drugset / Trial / NCT06091410

Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines

NCT06091410

RandomizedParallel-groupOpen-labelBasic science

Summary

The goal is to evaluate the in-depth immunogenicity analysis (including B-cell and T-cell response) of coadministration of a omicron-containing COVID-19 vaccine and influenza vaccine among healthy adults during 2023-24 season.

Timeline

Start
2023-09-25
Primary completion
2025-02-25
Completion
2025-06-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Influenza Virus Vaccine Vaccine 0.5 ml
Subject Omicron-containing COVID-19 vaccine Messenger RNA (mRNA)

Indications